1445 related articles for article (PubMed ID: 27692837)
21. Prospective comparison of PI-RADS version 2 and qualitative in-house categorization system in detection of prostate cancer.
Gaur S; Harmon S; Mehralivand S; Bednarova S; Calio BP; Sugano D; Sidana A; Merino MJ; Pinto PA; Wood BJ; Shih JH; Choyke PL; Turkbey B
J Magn Reson Imaging; 2018 Nov; 48(5):1326-1335. PubMed ID: 29603833
[TBL] [Abstract][Full Text] [Related]
22. Multiparametric magnetic resonance imaging-transrectal ultrasound fusion-assisted biopsy for the diagnosis of local recurrence after radical prostatectomy.
Muller BG; Kaushal A; Sankineni S; Lita E; Hoang AN; George AK; Rais-Bahrami S; Kruecker J; Yan P; Xu S; de la Rosette JJ; Merino MJ; Wood BJ; Pinto PA; Choyke PL; Turkbey B
Urol Oncol; 2015 Oct; 33(10):425.e1-425.e6. PubMed ID: 26259666
[TBL] [Abstract][Full Text] [Related]
23. Prostate cancer detection rates of magnetic resonance imaging-guided prostate biopsy related to Prostate Imaging Reporting and Data System score.
Osses DF; van Asten JJ; Kieft GJ; Tijsterman JD
World J Urol; 2017 Feb; 35(2):207-212. PubMed ID: 27287889
[TBL] [Abstract][Full Text] [Related]
24. Predictive value of PI-RADS classification in MRI-directed transrectal ultrasound guided prostate biopsy.
NiMhurchu E; O'Kelly F; Murphy IG; Lavelle LP; Collins CD; Lennon G; Galvin D; Mulvin D; Quinlan D; McMahon CJ
Clin Radiol; 2016 Apr; 71(4):375-80. PubMed ID: 26880299
[TBL] [Abstract][Full Text] [Related]
25. Anterior Localization of Prostate Cancer Suspicious Lesions in 1,161 Patients Undergoing Magnetic Resonance Imaging/Ultrasound Fusion Guided Targeted Biopsies.
Leyh-Bannurah SR; Kachanov M; Beyersdorff D; Preisser F; Tilki D; Fisch M; Graefen M; Budäus L
J Urol; 2018 Nov; 200(5):1035-1040. PubMed ID: 29935274
[TBL] [Abstract][Full Text] [Related]
26. Predictive clinical features for negative histopathology of MRI/Ultrasound-fusion-guided prostate biopsy in patients with high likelihood of cancer at prostate MRI: Analysis from a urologic outpatient clinic1.
Apfelbeck M; Pfitzinger P; Bischoff R; Rath L; Buchner A; Mumm JN; Schlenker B; Stief CG; Chaloupka M; Clevert DA
Clin Hemorheol Microcirc; 2020; 76(4):503-511. PubMed ID: 33337358
[TBL] [Abstract][Full Text] [Related]
27. Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naïve patients.
Washino S; Okochi T; Saito K; Konishi T; Hirai M; Kobayashi Y; Miyagawa T
BJU Int; 2017 Feb; 119(2):225-233. PubMed ID: 26935594
[TBL] [Abstract][Full Text] [Related]
28. Comparison of PI-RADS v1 and v2 for multiparametric MRI detection of prostate cancer with whole-mount histological workup as reference standard.
Schaudinn A; Gawlitza J; Mucha S; Linder N; Franz T; Horn LC; Kahn T; Busse H
Eur J Radiol; 2019 Jul; 116():180-185. PubMed ID: 31153562
[TBL] [Abstract][Full Text] [Related]
29. Quantitative Apparent Diffusion Coefficient Derived From Diffusion-Weighted Imaging Has the Potential to Avoid Unnecessary MRI-Guided Biopsies of mpMRI-Detected PI-RADS 4 and 5 Lesions.
Polanec SH; Helbich TH; Bickel H; Wengert GJ; Pinker K; Spick C; Clauser P; Susani M; Shariat S; Baltzer PAT
Invest Radiol; 2018 Dec; 53(12):736-741. PubMed ID: 29985792
[TBL] [Abstract][Full Text] [Related]
30. Risk Stratification of Equivocal Lesions on Multiparametric Magnetic Resonance Imaging of the Prostate.
Ullrich T; Quentin M; Arsov C; Schmaltz AK; Tschischka A; Laqua N; Hiester A; Blondin D; Rabenalt R; Albers P; Antoch G; Schimmöller L
J Urol; 2018 Mar; 199(3):691-698. PubMed ID: 28941924
[TBL] [Abstract][Full Text] [Related]
31. MRI-Ultrasound Fusion Targeted Biopsy of Prostate Imaging Reporting and Data System Version 2 Category 5 Lesions Found False-Positive at Multiparametric Prostate MRI.
Sheridan AD; Nath SK; Aneja S; Syed JS; Pahade J; Mathur M; Sprenkle P; Weinreb JC; Spektor M
AJR Am J Roentgenol; 2018 May; 210(5):W218-W225. PubMed ID: 29489409
[TBL] [Abstract][Full Text] [Related]
32. 18F-Choline PET/MRI: The Additional Value of PET for MRI-Guided Transrectal Prostate Biopsies.
Piert M; Montgomery J; Kunju LP; Siddiqui J; Rogers V; Rajendiran T; Johnson TD; Shao X; Davenport MS
J Nucl Med; 2016 Jul; 57(7):1065-70. PubMed ID: 26985061
[TBL] [Abstract][Full Text] [Related]
33. Prevalence of Prostate Cancer in PI-RADS Version 2.1 Transition Zone Atypical Nodules Upgraded by Abnormal DWI: Correlation With MRI-Directed TRUS-Guided Targeted Biopsy.
Lim CS; Abreu-Gomez J; Carrion I; Schieda N
AJR Am J Roentgenol; 2021 Mar; 216(3):683-690. PubMed ID: 32755208
[No Abstract] [Full Text] [Related]
34. The diagnostic accuracy of multiparametric magnetic resonance imaging before biopsy in the detection of prostate cancer.
Otti VC; Miller C; Powell RJ; Thomas RM; McGrath JS
BJU Int; 2019 Jan; 123(1):82-90. PubMed ID: 29804315
[TBL] [Abstract][Full Text] [Related]
35. Integration and Diagnostic Accuracy of 3T Nonendorectal coil Prostate Magnetic Resonance Imaging in the Context of Active Surveillance.
Curci NE; Lane BR; Shankar PR; Noyes SL; Moriarity AK; Kubat A; Brede C; Montgomery JS; Auffenberg GB; Miller DC; Montie JE; George AK; Davenport MS
Urology; 2018 Jun; 116():137-143. PubMed ID: 29653121
[TBL] [Abstract][Full Text] [Related]
36. Targeted multiparametric magnetic resonance imaging/transrectal ultrasound-guided (mpMRI/TRUS) fusion prostate biopsy versus systematic random prostate biopsy: A comparative real-life study.
Pham THN; Schulze-Hagen MF; Rahnama'i MS
Cancer Rep (Hoboken); 2024 Feb; 7(2):e1962. PubMed ID: 38217298
[TBL] [Abstract][Full Text] [Related]
37. Utility of Multiparametric Magnetic Resonance Imaging With PI-RADS, Version 2, in Patients With Prostate Cancer Eligible for Active Surveillance: Which Radiologic Characteristics Can Predict Unfavorable Disease?
Kim H; Pak S; Park KJ; Kim MH; Kim JK; Kim M; You D; Jeong IG; Song C; Hong JH; Kim CS; Ahn H
Clin Genitourin Cancer; 2020 Feb; 18(1):50-55. PubMed ID: 31640913
[TBL] [Abstract][Full Text] [Related]
38. Detection of significant prostate cancer with magnetic resonance targeted biopsies--should transrectal ultrasound-magnetic resonance imaging fusion guided biopsies alone be a standard of care?
Delongchamps NB; Lefèvre A; Bouazza N; Beuvon F; Legman P; Cornud F
J Urol; 2015 Apr; 193(4):1198-204. PubMed ID: 25451824
[TBL] [Abstract][Full Text] [Related]
39. Optimizing Combined Magnetic Resonance Imaging (MRI)-Targeted and Systematic Biopsy Strategies: Sparing the Multiparametric MRI-Negative Transitional Zone in Presence of Exclusively Peripheral Multiparametric MRI-Suspect Lesions.
Kachanov M; Leyh-Bannurah SR; Roberts MJ; Sauer M; Beyersdorff D; Boiko S; Maurer T; Steuber T; Graefen M; Budäus L
J Urol; 2022 Feb; 207(2):333-340. PubMed ID: 34555925
[TBL] [Abstract][Full Text] [Related]
40. Cognitive MRI-TRUS fusion-targeted prostate biopsy according to PI-RADS classification in patients with prior negative systematic biopsy results.
Lai WJ; Wang HK; Liu HT; Park BK; Shen SH; Lin TP; Chung HJ; Huang YH; Chang YH
J Chin Med Assoc; 2016 Nov; 79(11):618-624. PubMed ID: 27567440
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
